An Open label Clinical Study to evaluate the safety and gastrointestinal tolerance(Product Compliance) of MaxvidaTM Advance in Hospitalized patients requiring isocaloric formulafor enteral tube feeding
An open label, balanced, randomized, two-treatment, two period, two-sequence, single oral dose, crossover, bioequivalence study of Nitrocontin Controlled Release tablet 2.6 mg (Nitroglycerin) of Modi-Mundi Pharma Pvt. Ltd., in comparison with Nitromint® Retard Controlled Release tablet 2.6 mg (Nitroglycerin) of M/s Egis Pharma, Hungary in healthy, adult, human subjects under fasting condition. - NIL
An Open label Clinical Study to evaluate the safety and gastrointestinal tolerance (Product Compliance) of MaxvidaTM HPHF in Hospitalized patients requiring enteral tube feeding - tube feeding trial
100 Clinical Results associated with Modi-Mundi Pharma Pvt Ltd.
0 Patents (Medical) associated with Modi-Mundi Pharma Pvt Ltd.
100 Deals associated with Modi-Mundi Pharma Pvt Ltd.
100 Translational Medicine associated with Modi-Mundi Pharma Pvt Ltd.